Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.
about
Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive ReviewThe Increasing Relevance of Tumour Histology in Determining Oncological Outcomes in Colorectal CancerTargeting the mTOR signaling pathway in neuroendocrine tumorsGastroenteropancreatic high-grade neuroendocrine carcinomaBRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphologyFavourable outcomes of (177)Lu-octreotate peptide receptor chemoradionuclide therapy in patients with FDG-avid neuroendocrine tumoursStreptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment StratificationNeuroendocrine Cancer, Therapeutic Strategies in G3 Cancers.Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement.New therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.Real-world study of everolimus in advanced progressive neuroendocrine tumors.Topotecan monotherapy in heavily pretreated patients with progressive advanced stage neuroendocrine carcinomasIrinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.Biologics in gastrointestinal and pancreatic neuroendocrine tumorsItalian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.Nonsurgical Strategies in Patients With NET Liver Metastases: A Protocol of Four Systematic Reviews.Multiple scalp metastases from colonic neuroendocrine carcinoma: case report and literature review.Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system.Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading.A retrospective review of 126 high-grade neuroendocrine carcinomas of the colon and rectum.Systematic Review and Meta-Analysis on the Role of Chemotherapy in Advanced and Metastatic Neuroendocrine Tumor (NET)Aggressive Locoregional Treatment Improves the Outcome of Liver Metastases from Grade 3 Gastroenteropancreatic Neuroendocrine TumorsManagement of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.Radiochemotherapy Versus Surgery in Nonmetastatic Anorectal Neuroendocrine Carcinoma: A Multicenter Study by the Association des Gastro-Entérologues OncologuesDoes the WHO 2010 classification of pancreatic neuroendocrine neoplasms accurately characterize pancreatic neuroendocrine carcinomas?Long-term outcomes and prognostic factors in 78 Japanese patients with advanced pancreatic neuroendocrine neoplasms: a single-center retrospective study.Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancyHigh Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer(68)Ga-DOTATOC PET and gene expression profile in patients with neuroendocrine carcinomas: strong correlation between PET tracer uptake and gene expression of somatostatin receptor subtype 2High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 PatientsGenetics of pancreatic neuroendocrine tumors: implications for the clinic.The Role of Capecitabine/Temozolomide in Metastatic Neuroendocrine Tumors.Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas.Combination of irinotecan and a platinum agent for poorly differentiated neuroendocrine carcinomas.Histological characterisation and prognostic evaluation of 62 gastric neuroendocrine carcinomas.Efficacy of topotecan in pretreated metastatic poorly differentiated extrapulmonary neuroendocrine carcinoma.A case of neuroendocrine carcinoma in the hepatic hilar lymph nodes concomitant with an adenocarcinoma of the gallbladder.A Case of Poorly Differentiated Large-Cell Neuroendocrine Carcinoma of the Cecum: A Rare Malignancy, with Review of the Literature.
P2860
Q26768483-8C0F6145-E8BD-413C-97EE-1E4EB2E75720Q26796255-A8885528-8A93-4AA6-A789-128E9C7F1BAFQ26852089-17291274-2282-49ED-AD04-1DBF2A34DB5CQ26998392-4FCE03AD-1A24-4E60-A265-3630616DE656Q27853371-561A33B9-A3E3-4F17-BAC1-1D0C80C9FCCBQ28078501-F549D55B-E8A9-4FE4-B1DB-A678D545E069Q28247667-AEF8E909-1193-4B47-91C9-53A87BF19C46Q28551275-2451FE27-24A1-4BA3-9281-50B91ED4DC9CQ30238552-1FE72E06-6F76-46F1-A193-A98518941D4AQ30249051-5BE20D83-B93F-4E89-AEE5-3CE1B5F4BFC2Q30364864-33569DDB-F697-4198-A9B3-ADC50485BCE1Q33417013-2BDCB1FB-D23F-496B-81D0-BE66E309223BQ33417320-6B37C638-897D-4D80-BD53-321E4B11FEA3Q33648996-6B749A7C-0FEE-41EC-B5F5-E649E9A4C8E5Q33895557-F6EAB990-BE25-49D5-BBE8-63568D856AD6Q34157385-BD657A27-7054-41A8-A009-EEF6C2F480D3Q34464857-4DC27F61-5C03-4254-A2ED-C2C575414B7BQ35115068-5E8FA09C-B7A3-4F81-A872-18371A512415Q35178055-24ACD1C9-5136-40D4-BE4F-D57B2105A61EQ35713556-8DB50F99-39C1-4E86-BCDD-2CC1D81095ADQ35843079-A2A7FC05-AB71-4C73-A37D-5F7B0678A699Q35907055-05A3572E-734D-433F-8AF4-E5CD96FE982EQ36065003-0BFC60CB-F534-49BD-B3DD-8F4649D4464CQ36153131-441DD9E3-CC85-4FD7-A4DF-D636DA4894A9Q36184629-F6D7EDE3-1126-4BA9-BE88-DE6D31D168D6Q36206880-168C52AA-5AA0-4A39-BC84-F0D07870FC73Q36300517-89FF6E66-4F49-41B4-B4AB-01B7F54D693DQ36344419-F4FD38F5-B6A2-4A16-8027-80137A76F226Q36413831-EB092B93-8BEB-47EB-8D37-DD168169E923Q36558409-0073A747-D701-4C1A-A590-D57520B0B99DQ36568335-2A70472C-1EA9-4D4A-B5BB-212C346C3587Q36948373-00572BFA-6383-461D-82AE-8F8EC4FC2794Q36960581-0B0B9C21-1CE8-4559-8D64-C2FEBF5D8E38Q37017037-426E074F-FEBC-4409-AE20-5AB82A89F5E3Q37182620-DBFE9959-38AE-4978-9349-853E25A35F08Q37246147-DCBBDA41-272B-4457-9983-2C703AEF7303Q37274363-F61988DD-F492-4C76-A2EE-D3E41C4A9D53Q37321147-ECAF065C-E6AD-488B-A39A-96C5F9B2E1C1Q37414815-F1DBFE5A-9ED1-47D9-9AE0-6F3069F95B7EQ37562989-4795C418-7EEA-4912-ADBD-28DFEB4E0EF3
P2860
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Predictive and prognostic fact ...... WHO G3): the NORDIC NEC study.
@en
Predictive and prognostic fact ...... tinal neuroendocrine carcinoma
@nl
type
label
Predictive and prognostic fact ...... WHO G3): the NORDIC NEC study.
@en
Predictive and prognostic fact ...... tinal neuroendocrine carcinoma
@nl
prefLabel
Predictive and prognostic fact ...... WHO G3): the NORDIC NEC study.
@en
Predictive and prognostic fact ...... tinal neuroendocrine carcinoma
@nl
P2093
P356
P1433
P1476
Predictive and prognostic fact ...... WHO G3): the NORDIC NEC study.
@en
P2093
B Federspiel
E Birkemeyer
E T Janson
E Thiis-Evensen
H Gronbaek
P304
P356
10.1093/ANNONC/MDS276
P577
2012-09-11T00:00:00Z